A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck Clinical Trial

— COMMENCE  

Official title:

A Phase Ib-II Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. A Study of the Dutch Head and Neck Society

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02054442
• Other study ID #: MOHN01
• Secondary ID: 2013-002886-20DH
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: August 2016
• Est. completion date: December 2022

Study information

• Verified date: March 2021
• Source: Radboud University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators will perform a randomized phase II study to investigate if the addition of cetuximab to MTX is beneficial for the patient. Because no data on this combination are available the investigators will start with a phase Ib study to investigate the feasibility of the schedule.

Description:

The addition of cetuximab to cisplatin and 5-FU in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) showed an improvement of overall survival (OS), progression free survival (PFS) and response rate (RR). However, cisplatin and 5-FU are toxic cytostatics for the vulnerable recurrent or metastatic SCCHN patient. As one of the primary goals in these patients is palliation, in some patients treatment with cisplatin, 5-FU and cetuximab is not feasible owing to a low performance score (PS of 2) or the patient refusal to receive chemotherapy, i.e. cisplatin and 5-FU, possibly influencing quality of life negatively.

Methotrexate is a cytostatic which has shown to have modest activity in recurrent or metastatic SCCHN. The RR is between 14 and 20%, the median PFS is 3 months, and there is no improvement in OS, which is only 6 months. Toxicity of MTX is very low. Patients with a PS of 2 can be treated with MTX. Patients refusing treatment with cisplatin, 5-FU and cetuximab, frequently choose MTX as palliative treatment.

No data are available on the combination of cetuximab and MTX. The investigators will perform a randomized phase II study to investigate if the addition of cetuximab to MTX is beneficial, i.e. an improvement in the PFS, for the patient. Because no data on this combination are available the investigators will start with a phase Ib study to investigate the feasibility of the schedule.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 52
• Est. completion date: December 2022
• Est. primary completion date: December 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Cytologically/histologically-proven SCCHN

• Recurrent or metastatic SCCHN

• At least one measurable lesion as determined by RECIST v1.1 is required. Lesions in previously irradiated areas should not be considered measurable unless there is clear evidence of progression in such lesions since the radiotherapy.

• No prior systemic treatment for recurrent or metastatic disease

• Primary site: (1) oral cavity, (2) oropharynx, (3) hypopharynx, (4) larynx, or (5) unknown primary squamous cell carcinoma in the head and neck region presenting originally with lymph node metastases (N1-N3).

• Time between prior treatment and inclusion in the study (> 3 months). Palliative RT in case of painful bone metastases is allowed in phase II and after 4 weeks in phase Ib

• Ineligible (due to medical co-morbidities) or intolerant to platinum-based therapy per medical history or refusing cisplatin-based chemotherapy by the patient

• WHO performance status 0-2.

• Age >18 years

• Adequate organ function and laboratory parameters as defined by:

• Absolute neutrophil count (ANC) = 1.5 x 109 /L

• Hemoglobin (Hb) = 9 g/dl 5.6 mmol/l (which may be achieved by transfusion)

• Platelets (PLT) = 100 x 109/L

• AST and ALT = 2.5 x ULN (upper limit of normal)

• Serum bilirubin = 1.5 x ULN

• Calculated creatinine clearance or MDRD > 60ml/min

• Recovered from all adverse events (AEs) of previous anti-cancer therapies. AEs related to prior radiotherapy are allowed.

• Written informed consent

Exclusion Criteria:

• Serious active infections

• Patients (M/F) with reproductive potential not implementing adequate contraceptives measures

• Prior treatment with EGFR inhibitors or MTX

• Concomitant (or within 4 weeks before randomization) administration of any other experimental drug under investigation

• Concurrent treatment with any other anti-cancer therapy.

• Central nervous system involvement

• Lung fibrosis

• Pleural effusion or ascites or other third space effusions

• History of another malignancy within 2 years prior to starting study treatment, except cured basal cell carcinoma of the skin, excised carcinoma in situ of the cervix, or other head and neck cancer.

• Pregnancy or lactation

• Any other condition that would, in the Investigator's judgment, preclude patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g. infection/inflammation, intestinal obstruction, social/psychological complications.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Squamous Cell Carcinoma of Head and Neck
• Squamous Cell Carcinoma of the Head and Neck

Intervention

Drug:
• Cetuximab
We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.
• Methotrexate

Locations

Country	Name	City	State
Netherlands	Medical Centre Haaglanden	Den Haag
Netherlands	Medisch Spectrum Twente	Enschede
Netherlands	Medical Centre Leeuwarden	Leeuwarden
Netherlands	Leiden University Medical Center	Leiden
Netherlands	Academisch Ziekenhuis Maastricht	Maastricht
Netherlands	Radboud university medical center	Nijmegen
Netherlands	Erasmus Medical Center	Rotterdam
Netherlands	St. Elisabeth Ziekenhuis	Tilburg

Sponsors (9)

Lead Sponsor	Collaborator
Radboud University	Academisch Ziekenhuis Maastricht, Elisabeth-TweeSteden Ziekenhuis, Erasmus Medical Center, Leiden University Medical Center, Medical Center Haaglanden, Medical Centre Leeuwarden, Medisch Spectrum Twente, Merck Serono International SA

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of dose limiting toxicity (DLT)	In the phase Ib study: toxicity scored with CTC v 4.0*; incidence of dose limiting toxicity (DLT) during the first 4 weeks after start of the combination	During the first 4 weeks after start of the combination MTX and cetuximab
Primary	Progression free survival	In the phase II study: progression free survival (PFS). The analysis of PFS can be performed as soon as the target event (progression or death) has been observed in 98 of the 114 subjects randomized.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
Secondary	Overall survival (OS)	Overall survival (OS) The analysis of OS can be performed as soon as the target event has been observed in 98 of the 114 subjects randomized.	Followed up to 12 months after randomization
Secondary	Response rate (RR)	The difference in RR rates between both treatment arms will be analyzed using a stratified Cochran Mantel Haenszel test at a one-sided alpha-level of 0.05. In addition to the response rates in both arms, the odds ratio will be reported together with 90% confidence intervals. The impact of various demographic and disease characteristics (e.g. HPV positivity), on RR will be investigated using an exploratory logistic regression model.	Till end of treatment